中生制药(01177.HK)治疗乳腺癌药物获批上市

阿斯达克财经
11 Dec 2024

中生制药(01177.HK) 公布,集团开发的“甲磺酸艾立布林注射液”(商品名为艾乐林)已获得国家药监局的上市批准,用于治疗既往接受过至少两种化疗方案的局部晚期或转移性乳腺癌患者。今次是国内前三款获批上市的甲磺酸艾立布林注射液。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-11 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10